Business: Investors Dream of Genes

Genentech, a pioneer in daring DNA research, goes public

The list of products by Genentech, a four-year-old San Francisco-based firm, reads like a cornucopia of blessings for mankind. It includes a hormone that may stimulate human growth, mass-produced human insulin that could reduce the cost of treating diabetes, and interferon (TIME, March 31), which may be used to treat everything from cancer to the common cold. Shares of Genentech are expected to go on sale soon on the over-the-counter market, and investors are queuing up to buy what some believe will be one of...

Want the full story?

Subscribe Now

Subscribe
Subscribe

Get TIME the way you want it

  • One Week Digital Pass — $4.99
  • Monthly Pay-As-You-Go DIGITAL ACCESS$2.99
  • One Year ALL ACCESSJust $30!   Best Deal!
    Print Magazine + Digital Edition + Subscriber-only Content on TIME.com

Learn more about the benefits of being a TIME subscriber

If you are already a subscriber sign up — registration is free!